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A B S T R A C T
Progressive neuronal death is the key pathogenic event leading to clinical symptoms in neurodegenerative
disorders (NDDs). Neuroprotective treatments are virtually unavailable, partly because of the marked internal
heterogeneity of the mechanisms underlying pathology. Targeted neuroprotection would require deep me-
chanistic knowledge across the entire aetiological spectrum of each NDD and the development of tailored
treatments. Although ideal, this strategy appears challenging, as it would require a degree of characterization of
both the disease and the patient that is currently unavailable. The alternate strategy is to search for common-
alities across molecularly distinct NDD forms and exploit these for the development of drugs with broad-spec-
trum efficacy. In this view, mounting evidence points to ionic mechanisms (IMs) as targets with potential
therapeutic efficacy across distinct NDD subtypes. The scope of this review is to present clinical and preclinical
evidence supporting the link between disruption of IMs and neuronal death in specific NDDs and to critically
revise past and ongoing attempts of harnessing IMs for the development of neuroprotective treatments.
https://doi.org/10.1016/j.phrs.2019.104343
Received 8 May 2019; Received in revised form 19 June 2019; Accepted 3 July 2019
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; anle138b, 3-(1,3-Benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole,5-(1,3-Benzodioxol-
5-yl)-3-(3-bromophenyl)-1H-pyrazole; AP, action potential; ATXN, ataxin; BEST1, bestrophin1; BK/SK channels, large/small conductance,Ca2+-sensitive K+ chan-
nels; CaV, voltage-gated calcium channel; CNG channel, cyclic nucleotide-gated channel; DN, dominant negative; DRD, degenerative retinal disorders; EC, entorhinal
cortex; GABA, γ-aminobutyric acid; GIRK, G protein-activated inward-rectifying K+ channel; GOF, gain of function; HCN channels, Hyperpolarization-activated
cyclic-nucleotide gated channels; Inap, persistent sodium current; IP3R1, Type 1 Inositol 1,4,5-trisphosphate receptor; KATP channel, ATP-sensitive potassium
channel; KCa channels, Ca2+-sensitive K+ channels; KV, voltage-gated potassium channel; L-DOPA, L-3,4-dihydroxyphenylalanine; LOF, loss of function; mGluR1,
Type1 metabotropic glutamate receptor; MN, motor neuron; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; mPTP, mitochondrial permeability transition
pore; MPP+, 1-methyl-4-phenylpyridinium; NaV, voltage-gated sodium channel; NCX, Na+/Ca2+ exchanger; NDD, neurodegenerative disorder; NMDA, N-methyl-D-
Aspartate; 6−OHDA, &-hydroxydopamine; OXPHOS, oxidative phosphorylation; PD, Parkinson’s disease; PN, Purkinje neuron; RP, retinitis pigmentosa; ROS, reactive
oxygen species; RyR, ryanodine receptor; SNc, substantia nigra pars compacta; SCA, spinocerebellar ataxia; SOD1, superoxide dismutase 1; TBP, TATA box binding
protein; TEA, tetraethylammonium; TRPC3, Transient receptor potential “canonical” type 3; VTA, ventral tegmental area
⁎ Corresponding author.
E-mail address: alessio.masi@unifi.it (A. Masi).
1 equal contribution.
Pharmacological Research 147 (2019) 104343
Available online 04 July 2019
1043-6618/ © 2019 Elsevier Ltd. All rights reserved.
T
1. Introduction
NDDs are typically defined as disorders of the nervous system in
which slow but relentless cell death is the primary pathogenic event.
Clinical manifestations typically mirror the pathophysiological altera-
tions resulting from neuronal loss. NDDs are progressive and, since no
cures are available, generally lethal. For some NDD classes, age is the
main risk factor, hence the economic burden for the health systems of
modern societies is constantly increasing due to rising life expectancy.
While the optimal intervention would be neuroprotection, only treat-
ments with partial symptomatic efficacy are currently available. When
symptomatic treatments exist, as in the case of dopamine replacement
therapy for Parkinson’s Disease (PD), relief is transient and oftentimes
associated to severe side effects. For other NDD classes, such as
Alzheimer’s disease (AD), even the management of symptoms is un-
satisfactory. Overall, the massive effort made with both public and
private investments in the quest for neuroprotective therapies has been
largely frustrated by the disappointing outcomes of clinical trials.
Nonetheless, thanks to progresses made by genetic studies and the
widespread utilization of disease animal models, significant steps for-
ward have been taken in the comprehension of the pathogenic path-
ways underlying NDDs. Besides confirming the high degree of aetio-
pathogenic diversity across different NDDs, which is hardly surprising,
an unexpected level of internal heterogeneity in the pathogenic me-
chanisms underlying individual NDD classes has emerged [1–4], thus
supporting the proposition that NDDs are mere clinical entities in which
defining symptoms arise from diverse molecular pathways. For trans-
lational prospects, the mechanistic complexity of NDD pathogenesis
implies that multiple targets should be identified for each NDD subtype,
to design specific neuroprotective therapies. An alternate option is to
exploit common disease pathways with established pathogenic re-
levance across NDD subtypes, or even NDD classes, to develop treat-
ments with broad-spectrum efficacy. In the following paragraphs, we
will present multiple lines of evidence suggesting that mechanisms
controlling the activity of principal ions, such as Na+, K+, Ca2+, Cl−
(henceforth collectively referred to as ionic mechanisms, IMs) and
thereby the electrical properties of the neuron, are in the right position
to serve as targets endowed with such potential. IMs take part in neu-
rodegenerative processes at multiple levels and in complex ways. In
some diseases, the IMs underlying neuron-specific electrical properties
may cause heightened sensitivity towards genetically-determined or
environmental risk factors. In other cases, innate or acquired defects in
IMs shaping the electrical profile of the neuron may drive disease
progression. In either case, pathogenic steps driven by IMs are found at
the crossroads of multiple pathways across molecularly distinct NDD
subtypes, or even across distinct diseases. The present article aims at
providing a non-systematic, critical revision of preclinical and clinical
evidence supporting the existence of a causal link between IMs func-
tion/dysfunction and neuronal degeneration. To this aim, we will first
concisely overview common terminal events causing neuronal death
across diverse NDD classes. Afterwards, we will consider selected NDD
classes where IMs have been involved in pathogenesis or used as
pharmacological targets, in preclinical or clinical settings, in the at-
tempt to achieve disease modification.
2. Terminal cell death mechanisms activated by IMs-related
pathogenic pathways in NDDs
Neurons are excitable cells whose electrical properties are governed
by the expression and activity of a large complement of IMs. IMs de-
termine the polarity and magnitude of resting membrane potential,
support the generation and propagation of the action potential (AP) and
enable synaptic transmission. In the classical view, IMs are seen as
downstream elements of the biological information flow, their function
being controlled by transcription level, post-translational modifica-
tions, subcellular distribution pattern and physical interaction with
ancillary subunits or membrane constituents. In physiological condi-
tions, IMs function does not impinge on the overall health state of the
neuron. When these are dysfunctional, however, normal electrical ac-
tivity is disrupted and neurological disorders may occur. In some cases,
the link between clinical manifestations and defective electrical prop-
erties is direct. In epilepsy, the prototypical ion channel-related disease
(or “channelopathy”), mutations in specific classes of voltage-gated ion
channels cause elevated spike probability at single neuron level and the
occurrence of hypersynchronous activity [5]. Neurodegeneration may
appear in advanced stages of the disease as a long-term consequence of
exceeding glutamate release and N-methyl-D-aspartate (NMDA) re-
ceptor-mediated Ca2+ overload on postsynaptic neurons, a phenom-
enon known as “excitotoxicity”. However, neuronal death is not the
cause of pathophysiological alterations in epilepsy, but rather a con-
sequence of these [6]. Therefore, effective management of symptoms
prevents neuronal death [7]. In NDDs, in contrast, neuronal death is the
key pathogenic event, that normally precedes or accompany sympto-
matology. In this class of neurological disorders, numerous alterations
have been associated to neuronal death in a limited number of path-
ways, including energy metabolism, mitochondrial function/redox
state, protein turnover. In this picture, IMs may drive disease in three
manners. First, the normal neuronal complement of IMs may result in
intrinsic vulnerability towards genetically-encoded or sporadic disease
causes/risk factors. Hence, IMs add to other determinants, such as
morphology, energy demand, constitutive ROS production, neuro-
chemical and protein content, in shaping an innate, cell type-specific
vulnerable phenotype. Second, the activation of disease pathways of
diverse nature may disrupt physiological IMs operation. Acquired
functional alteration may in turn engender a pathological electrical
phenotype promoting cell death. Third, mutations in IMs-encoding
genes may be the primary cause of neuropathology, cell death and
neurological manifestations. Although uncommon, these “neurodegen-
erative channelopathies” are very instructive, as they reflect the strong
relation of causality and sufficiency that may establish between ionic
signalling and neuronal death.
Early evidence for the capability of dysfunctional IMs to trigger
degenerative neuronal death comes from mechanistic studies in animal
models. The weaver mutation in the mouse is a paradigmatic case of
neurodegenerative channelopathy. The weaver neurological phenotype,
characterized by ataxia and gait abnormalities, is caused by a sponta-
neous, single nucleotide substitution in the KCNJ6 gene, encoding the G
protein-activated inward-rectifying K+ channel (GIRK) 2 [143]. Be-
cause of the nucleotide switch, the channel turns into a nonselective,
constitutively active cation conductance. Dopaminergic (DAergic)
neurons of the substantia nigra pars compacta (SNc) in brain slices pre-
pared from these mice show depolarized membrane potential, absence
of spontaneous firing and increased membrane conductance [8]. In
association to aberrant electrophysiological phenotype, homozygous
weaver mice develop distinctive neuropathology including SNc-specific
DAergic degeneration [143] between postnatal days 7 and 21. The re-
markable neuropathological phenotype caused by the weaver mutation
is a milestone for the study of the interplay between IMs and neuronal
survival, as it provides hard evidence that a single-nucleotide, gain-of-
function mutation in a membrane-resident ion channel, besides altering
single-cell electrophysiological properties, can put at risk the very
survival of the neuron. Finally, the weavermouse highlights the concept
of differential vulnerability. Expression of GIRK2 channels is wide-
spread in the brain, yet only a few populations are affected by the
mutation, indicating that some populations are more susceptible to the
detrimental effects of changes in their electrical phenotype [8].
A detailed description of the chemical and molecular events trig-
gering death pathways at single cell level is beyond the scope and the
possibilities of this review. However, for the sake of completeness, it is
necessary to mention the cellular mechanisms which play a critical role
in transducing ionic dyshomeostasis or altered electrical properties in a
death signal. Fig. 1 shows an overview of the main death pathways
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leading to cell death when IMs are disrupted in NDDs. Details on these
pathways, along with references to excellent reviews addressing this
topic, can be found in the figure legend.
The main link between IMs and neuronal fate is the interplay with
energy metabolism and the redox state of the cell. The maintenance of
electrochemical gradients across biological membranes, required for
normal neuronal operation, comes to high metabolic cost. While
representing 2% of the total body weight, the brain accounts for 20% of
all the oxygen and energy consumed by the body [9,10]. Intense mi-
tochondrial activity is necessary to produce the ATP required for active
ionic transport mechanisms. Massive ATP amounts are constantly
consumed by the Na+/K+ and Ca2+ ATPases to sustain the physiolo-
gical resting membrane potential and the steep Ca2+ gradient across
the plasma membrane and the endoplasmic reticulum (ER) membrane.
Fig. 1. Common cell death mechanisms triggered by IMs-related pathways underlying NDDs.
Left, healthy neuron: intracellular ATP concentration and synthesis is normal and sufficient for the maintenance of all the ionic gradients sustained by the activity of
primary and secondary active transporters. Resting membrane potential (VM) is normal (˜60mV) and cytosolic Ca2+ concentration is kept in the submicromolar
range by the sustained activity of extracellular (PMCA and NCX) and ER membrane transporters/pumps (SERCA). Inset: scheme of the electron transport chain (ETC).
Cytochrome c is loosely associated to the ETC and transfers electrons from complex III to complex IV. ATP production is optimal and the reactive oxygen species
(ROS) released by this process are quenched by mitochondrial and cytosolic scavengers. Mitochondrial membrane potential (ΔΨm) is highly polarized (−150mV).
Because of the low cytosolic Ca2+ concentration, the activity of voltage-dependent anion channel (VDAC) and the mitochondrial calcium uniporter (MCU) is low,
resulting in minimal concentration of Ca2+ inside the mitochondria. In presence of low mitochondrial Ca2+ and ROS levels the mitochondrial permeability transition
pore (mPTP) is mostly in the closed state. Major pro-apoptotic proteins, such as cytochrome c and apoptosis-inducing factor (AIF) are either confined inside the
mitochondria or in an inactive state in the cytosol (BAK, BAX and calpain).
Right, pathological context (numeration is not indicative of chronological order). (1) Cytosolic Ca2+ concentration rises following the activation of NMDAR, CaV and
Ca2+-permeable AMPAR. (2) Increased cytosolic Ca2+ concentration causes calcium-induced-calcium-release (CICR), leading to Ca2+ outflow from the ER lumen
through RyR and IP3R [11]. (3) Ca2+ influx inside the mitochondrial matrix through VDAC and MCU causes an increase in ROS production followed by cytochrome c
oxidation [12]. Elevated ROS and Ca2+ concentrations causes mPTP opening, additional release of Ca2+ in the cytosol and massive entry of water and solutes into the
mitochondria, which eventually lead to organelle swelling and rupture of the outer membrane [12]. (4) Cytochrome c is released in the intermembrane space and
ATP production diminishes [13]. The decrease in ETC efficiency leads to general energy shortage [14], slowing the activity of transporters and thus further increasing
intracellular Ca2+ concentration. (5) Ca2+-activated calpain cleaves cytosolic BAX, that assembles with BAK and mitochondrial proteins to form the mitochondrial
apoptosis-induced channel (MAC) [15,16]. This complex boosts RyR and IP3R activity [17] and promotes the degradation of cytosolic substrates [18]. Elevated ROS
production overwhelms the quenching activity exerted by scavengers causing lipid peroxidation and additional boosting of RyR activity. (6) Apoptosis is also driven
by two additional processes consisting in the formation of the apoptosome, a protein complex including cytochrome c leaked out of mitochondria through MAC
[15,16] and the translocation of AIF into the nucleus, responsible for chromatin condensation and DNA fragmentation [19].
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Deviations from physiological ionic homeostasis may result from a
number of alterations in any of the IMs mediating active and passive
ionic fluxes. In spite of the great heterogeneity of alterations, the
terminal events ultimately determining neuronal demise are essentially
two: pathological Ca2+ signalling and oxidative stress.
Ca2+-mediated processes are involved in nearly all physiological
activities of the healthy neuron. Physiological Ca2+ transients are
generally spatially-confined and short-lasting. This is permitted by the
action of ATP-dependent Ca2+-clearing mechanisms. Ca2+ dysho-
meostasis is a major cell death trigger, not only in neuronal cells, and
prolonged deviations from physiological intracellular Ca2+ concentra-
tion triggers a host of cellular pathways eventually causing cell death,
including the calpain cascade, resulting in degradation of cytoskeletal
proteins and apoptotic death. Elevated cytosolic Ca2+ activates feed-
forward processes such as a calcium-induced calcium release (CICR),
mediated by ER-resident Ca2+ conductances such as the ryanodine
receptor (RyR) and the Inositol 1,4,5-trisphosphate receptor (IP3R).
In normal conditions, mitochondria are low-affinity, high-capacity
Ca2+ reservoirs. Moderate increase in Ca2+ levels in the matrix is
perceived as an elevated ATP demand. Therefore, Krebs cycle and
oxidative phosphorylation (OXPHOS) are stimulated. The latter is the
primary source of reactive oxygen species (ROS) in the cell. ROS are
very reactive, yet short lived, molecules which are normally neutralized
by scavenging enzymes, such as superoxide dismutase (SOD) and cat-
alase. When ROS production, due to high ATP demand, exceeds the
cellular scavenging capacity, oxidative stress may occur. Elevated cy-
tosolic Ca2+ may result from a variety of electrophysiological aberra-
tions, including hyperexcitability, pathological activation of plasma
membrane CaV channels or Ca2+-permeable glutamate receptors, such
as the NMDA receptor.
3. Parkinson’s disease
Parkinson’s Disease (PD) is the second most common NDD in de-
veloped countries, with a prevalence of about 2% in the population
over 65 years of age [20]. Typical motor symptoms, such as resting
tremor, rigidity and bradykinesia, result from the massive degeneration
of dopamine (DA) neurons of the substantia nigra pars compacta (SNc)
and ensuing reduction of DA levels in dorsal striatum, a subcortical
structure involved in the control of voluntary movement. The vast
majority (˜90%) of PD cases have sporadic nature, the remaining cases
being caused by fifteen disease-causing monogenic mutations denomi-
nated PARK 1–15 [21,22]. In addition to genetic causes, 26 genetic risk
factors have been identified by genome-wide association studies [1,22],
suggesting the existence of great heterogeneity in the mechanisms
leading to clinical PD. The incomplete understanding of such complex
pathogenic scenario has been suggested as the main cause for the
failure of disease-modifying drugs in clinical trials [23]. In spite of the
etiopathogenic diversity, there is evidence that multiple disease-causing
factors converge to determine a relatively homogeneous pathological
scenario in PD, which includes mitochondrial deficit, oxidative stress
and impaired protein turnover [24]. In the past 15 years, a number of
studies have focused on IMs in search for determinants of the vulner-
able DAergic phenotype [25,26]. Midbrain DAergic neurons are char-
acterized by unstable membrane potential and intrinsic AP generation
[27]. Spontaneous firing activity is sustained by the coordinated action
of a large complement of voltage-gated ion channels expressed in the
somatodendritic compartment [28], which requires continuous re-
storation of ionic gradients across the plasma membrane by active
transport systems and intense ATP consumption [10]. ATP levels must
be constantly restored by oxidative OXPHOS in mitochondria. Mi-
tochondrial OXPHOS is the main source of reactive oxygen species
(ROS) in the cell, and when ROS production exceeds the scavenging
capacity of redox systems, oxidative stress may occur. Oxidative stress
causes non-specific chemical damage to cellular constituents, such as
membrane lipids, proteins and nucleic acids, with lethal consequences
for the cell [29]. Mitochondrial function, ROS metabolism and IMs are
interconnected and exert reciprocal influence. ATP-sensitive (KATP)
potassium channels are a striking example of a plasma membrane IM
under metabolic control [30]. KATP channels are negatively regulated
by ATP levels, thus they open in presence of low intracellular ATP
causing membrane hyperpolarization and silencing of the electrical
activity. KATP channels are widely expressed in nerve cells, where they
are thought to serve as metabolic sensors braking energy-demanding
electrical activity in case of ATP supply shortage [31,32]. In the early
2000s, Roeper and co-workers demonstrated that KATP channels in SNc
DAergic neurons are particularly sensitive to the metabolic failure in-
duced by MPTP or rotenone, two chemically distinct complex I blockers
used to generate animal models of environmental PD. Both ATP de-
pletion and perfusion of complex I blockers cause activation of KATP
channels, reduction of firing rate and neuronal silencing during brain
slice recordings. The additional finding that genetic inactivation of KATP
channels reduces nigrostriatal degeneration in the MPTP-intoxicated
and weaver mouse models suggests that KATP channels activation is a
mechanism of broad relevance in DAergic degeneration [33]. To ex-
plain how KATP-dependent electrical silencing may cause selective ni-
grostriatal DAergic degeneration, the authors have proposed a neuro-
physiological version of the “use it or lose it” evolutionary theory.
According to this hypothesis, individual neurons experiencing persis-
tent reduction or complete silencing of their electrical activity, even-
tually undergo apoptotic cell death [34]. The experiments linking KATP
engagement and Parkinson-like neurodegeneration attracted great in-
terest in the following years. Mercuri and co-workers demonstrated that
KATP in SNc DAergic neurons are gated by the mitochondrial toxin ro-
tenone [35] and inhibited by memantine, a non-competitive glutamate
NMDA receptor antagonist which showed neuroprotective efficacy in
animal models [36]. A more recent study reported the neuroprotective
effect of K+ATP blockade in PD animal models [37]. In this work, the KATP
blocker and antidiabetic glibenclamide was able to protect from
6−OHDA-induced nigrostriatal lesion. In spite of the compelling ex-
perimental evidence linking K+ATP channels activation to nigrostriatal
degeneration in preclinical models, the lack of disease specificity and
the critical involvement in the regulation of blood glucose level may
have hindered further exploitation of this target. As of today, mod-
ulators of KATP channels have never been tested in clinical trials.
The recapitulation of molecular pathways causing selective vul-
nerability of SNc DAergic neurons triggers electrophysiological ab-
normalities which have been proposed to determine the vulnerable
neuronal phenotype in PD animal models. These abnormalities often
involve the disruption of cell-autonomous mechanisms controlling in-
trinsic generation of rhythm. Electrophysiological recordings from
single neurons in vivo demonstrated that pharmacological inhibition of
the Ubiquitin-proteasome system (UPS) causes acceleration of the firing
frequency in surviving SNc but not VTA DAergic neurons. Post hoc
histological examination showed SNc-limited loss of DAergic neurons,
thus establishing a strong, yet associative, link between electrical al-
terations and neurodegeneration [38]. Selective increase of firing fre-
quencies in SNc DAergic neurons was also reported in transgenic mice
expressing a mutant form of the human α-synuclein (A53T-SNCA) be-
fore symptoms onset. At molecular level, the alteration in firing rate
was partly mediated by a functional impairment of A-type KV 4.3 po-
tassium channels. Oxidative dysfunction of the channel was proposed as
the mechanism linking mutant α-synuclein and functional alteration, as
this was prevented by glutathione perfusion [39]. Although the de-
monstration of a mechanistic link between IMs dysfunction and neu-
rodegeneration is lacking, these reports indicate that distinct PD-re-
levant pathogenic pathways selectively disturb the normal electrical
activity in vulnerable neurons. Moreover, at least in the latter study,
electrophysiological alterations induced by the mutation are manifest at
early stage of disease progression, suggesting that they may represent
potential targets for disease modification.
As mentioned, the functional coupling between energy metabolism
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and IMs is bidirectional, and the activity of certain membrane con-
ductances may affect the energy demand of the neuron. Elevated me-
tabolic activity required to meet the energy request may in turn act as a
susceptibility factor towards genetic or sporadic risk factors and the IMs
imposing such metabolic burden on the neuron represent ideal targets
for protective medications with therapeutic relevance across the entire
aetiological spectrum of PD. By using electrophysiology, pharmacology
and calcium imaging in brain slices, DJ Surmeier and co-workers
showed that SNc DAergic neurons in rodent brain slices display den-
dritic Ca2+ oscillations, which are phase-locked to, but not required for
intrinsic firing activity [40]. The authors showed that dendritic Ca2+
oscillations are mediated by CaV1.3, and that constant removal of Ca2+
from the cytosol poses a significant metabolic burden for the neuron
[41]. To keep up with ATP-demanding Ca2+ pumps, mitochondria need
to maintain relatively high rates of ATP production, which result in
high levels of ROS generation. Furthermore, it was proved that SNc
DAergic neurons have higher OXPHOS basal activity and associated
ROS production compared to nearby VTA DAergic neurons and that
isradipine, a CaV 1.2–1.3 blocker, stops dendritic Ca2+ oscillations and
lowers oxidative stress in physiological conditions [42] as well as in
presence of PD-relevant mutations [41,43]. Furthermore, isradipine
was shown to afford protection from nigrostriatal neurodegneration in
a 6−OHDA mouse model [44]. Isradipine is a dihydropiridine with
negative allosteric modulation activity and equal affinity for CaV 1.2
and 1.3, already approved by FDA and other regulatory bodies for the
treatment of high blood pressure (DynaCirc™). Building on the pro-
mising preclinical studies described above, isradipine is now being
tested in a phase III clinical trial named STEADY-PD III (ID:
NCT02168842). STEADY-PD III is a double-blind, randomized, placebo-
controlled study, started in 2014 and to be completed in March 2019.
The study, involving 336 participants with early stage clinical PD, not
receiving or requiring symptomatic therapy at start date, aims at testing
the neuroprotective efficacy of isradipine over the 36-month trial
period, as measured with the total Unified Parkinson Disease Rating
Scale (UPDRS) score [45]. So far, this is the only clinical trial based on
the modulation of an IM as a neuroprotective approach in PD. Of note,
the rationale at the basis of the study is supported by retrospective
population studies associating the use of centrally-acting Ca2+-blockers
to a significant (˜30%) reduction in the risk of developing PD [46,47].
More recently, another family of voltage-gated ion channels has
been proposed as an intrinsic determinant of the vulnerable phenotype
of SNc DAergic neurons. With brain slice patch clamp recordings, the
authors of the present manuscript demonstrated that the PD-causing
toxin MPP+ inhibits Hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels in SNc DAergic neurons [48]. HCN channels
conduct a hyperpolarization-activated, inward cationic current which
promotes pace-making and controls synaptic excitability [48–50]. In
SNc Daergic neurons, HCN current is carried by the HCN2 and 4 iso-
forms, which distinguish themselves from isoforms 1 and 3 for higher
cAMP sensitivity [51]. HCN current inhibition causes rapid reduction of
autonomous spiking and marked increase in synaptic excitability [48].
Furthermore, the electrophysiological effects exerted by pharmacolo-
gical inhibition of HCN current, as well as the ensuing somatic Ca2+
inflow, is larger in vulnerable SNc as compared to resistant VTA
DAergic neurons [52]. Finally, it was shown that chronic inhibition of
HCN current attained with local administration of two distinct HCN
blockers, causes DAergic neuronal death in the SNc, but not in the VTA,
of normal adult rats [53]. Based on their results, the authors speculate
that HCN current may undergo loss of function (LOF) during the early
phases of disease progression, possibly as a consequence of metabolic
fatigue, and drive Ca2+-mediated toxicity, thus representing an SNc-
specific pathogenic pathway. Because no association between HCN
mutations and PD have been discovered so far, it remains to be de-
termined whether HCN LOF participates in the pathogenic cascade of
clinical PD and how genetic or sporadic PD-triggers induce HCN LOF. In
this respect, it was demonstrated the HCN current is negatively
modulated by acute inhibition of mitochondrial ATP production, an
effect resembling that induced by low intracellular cAMP [53]. It is
plausible that metabolic stress and reduced ATP production result in
reduced cAMP synthesis in preclinical stages of PD. In agreement with
this proposition, HCN LOF was reported in SNc DAergic neurons of
early stage Mitopark mice, an animal model in which a Cre-dependent,
DAergic-restricted mitochondrial mutation drives late-onset, slow-pro-
gressing nigrostriatal degeneration and, eventually, PD motor symp-
toms [54,55]. For translational prospects, HCN channels can be envi-
sioned as amenable pharmacological targets. However, experimental
data point to inverse causal relation between HCN current and PD pa-
thogenesis. In other words, according the HCN hypothesis, neuropro-
tection would be afforded in PD by functional enhancers. The design of
ion channels’ enhancers is a highly challenging endeavour for medicinal
chemistry and specific HCN enhancers are not yet available [56]. No
ongoing clinical studies are directly testing the neuroprotective efficacy
of HCN functional rescue. However, there is preclinical and clinical
evidence consistent with a contribution of HCN LOF in PD-related
neurodegeneration. The anticonvulsant drug lamotrigine, which also
shows HCN-enhancing action in DAergic neurons [57] protects from
MPTP-induced degeneration [58]. In the latter report, two different
anticonvulsants devoid of HCN-boosting activity such as topiramate
and valproate failed to afford neuroprotection, suggesting that the
neuroprotective effect exerted by lamotrigine may be HCN-mediated.
Recently, a large observational clinical study showed that subjects
taking salbutamol for the treatment of asthma have reduced risk of
developing PD [59]. Salbutamol is a brain-penetrant β2 adrenergic re-
ceptor agonist stimulating intracellular cAMP synthesis. Although it
was not tested in these studies, it is tempting to speculate that HCN
upregulation contributes to the neuroprotective effect of these drugs.
Altogether, preclinical and clinical data prompt to investigate in more
detail the potential of HCN channels as targets for neuroprotection in
PD.
The hypothesis of a contribution of excitotoxicity to PD pathogen-
esis has provided the rationale for preclinical and clinical studies in the
past. Memantine has been extensively studied in preclinical models and
in clinical trials as a neuroprotective agent in PD and other NDDs be-
cause of its presumed anti-excitotoxic action. Clinical trials have pro-
vided modest results in the management of PD-related cognitive decline
[60] and motor symptoms [61] while there is no evidence in the lit-
erature of a clinical study testing memantine as a neuroprotectant in
prodromic or early-stage PD patients. Based on the same rationale, the
voltage-gated Na+ channel blocker riluzole is proposed to counteract
the excitoxic component in NDDs and thus currently used in the therapy
of ALS. Riluzole has been tested for many years as a neuroprotectant
also in preclinical models of PD, with modest results [62]. One single
study has tested riluzole in early-stage PD patients in 2002 failing to
show any beneficial effect on clinical manifestations, although the short
duration (≤1 year) and the very small sample (20 patients) may have
weakened the power of this study [63]. Fig. 2 (top) illustrates major
contributions of IMs to PD pathogenesis, according to the current un-
derstanding.
4. Alzheimer’s disease
Alzheimer's disease (AD) is the primary cause of dementia in wes-
tern societies. At onset, disease symptoms may be subtle and go un-
noticed, but the inevitable progression leads to severe cognitive im-
pairment and, eventually, death. The main neuropathological hallmarks
are extracellular deposition of β-amyloid (Aβ) plaques and intracellular
accumulation of neurofibrillary tangles containing hyperpho-
sphorylated tau protein [64–66]. The aetiology of the disease is es-
sentially unknown and the vast majority of cases are sporadic. Some
hints on the molecular aspects of the disease come from the study of
genes mutated in familial forms. Patients with familial AD, character-
ized by early age of onset (< 50 years), carry mutations in genes
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Fig. 2. Role of IMs and altered electrical activity in the pathogenic processes underlying selected NDDs.
Each panel depicts the normal condition (left hand) and the pathological context (right hand). Drugs are divided based on stage of exploitation in clinical relevance.
In dark blue, those employed as disease modifiers, in light blue those still in a preclinical stage.
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encoding amyloid precursor protein (APP), presenilin 1 and presenilin
2, all involved in the formation of Aβ oligomers. Studies on these
pathways have led to the hypothesis that Aβ self-aggregation and
plaque formation is the key pathogenic process in AD, although the
details of the link between neuropathological alterations and neuronal
cell death are incompletely understood. While there is increasing evi-
dence pointing to remarkable genetic and molecular heterogeneity in
AD [3,67], calcium dysregulation has emerged as a common denomi-
nator driving neuronal death [68–70]. A great deal of interest was
raised by early studies showing that Aβ oligomers were able to directly
perturb Ca2+ homeostasis in cellular systems. Patch clamp recordings
obtained from excised membrane patches incubated in the presence of
Aβ oligomers showed that these can assemble to form Ca2+-permeable
pores in the plasma membrane [71–73]. It has been recently demon-
strated that the Aβ 1–42 peptide, but not the related 1–40 peptide, is
responsible for the formation of membrane pores [74].
In addition to the remarkable example of Aβ oligomers, in which the
disease determinant acts as an aberrant IM itself, IMs may promote AD
pathogenesis subsequently to the activation of AD-related pathways.
Indeed, numerous reports indicate that Aβ oligomers may affect a
number of IMs in the cell membrane and thereby drive neuronal toxi-
city. In the cholinergic septal cell line SN56, Aβ peptides induce acti-
vation of Tetraethylammonium (TEA)-sensitive outward K+ currents.
Pharmacological blockade of K+ currents prevents Aβ-induced toxicity
[75]. In cultured hippocampal neurons, incubation with a synthetic Aβ
peptide causes a reversible voltage-dependent increase in membrane
resistance, resulting from the inhibition of a fast-inactivating KV
channel [76]. In the same experimental model, exposure to Aβ 1–40 or
Aβ 25–35 causes rapid and selective reduction in Na+/K+ ATPase ac-
tivity leading to membrane depolarization, disruption of Ca2+ home-
ostasis and cellular degeneration [77]. Additional pathogenic interac-
tions between AD-related mutations and IMs have emerged in more
recent years, mainly from studies employing the 3XTgAD mouse model,
a triple transgenic line carrying mutations causing autosomal dominant
forms of clinical Alzheimer’s and Frontotemporal Dementia [78]. In
dissociated neurons obtained from 3XTgAD mice, the KATP channel
opener diazoxide is able to revert pathological changes in excitability,
Ca2+ homeostasis and bioenergetics, while chronic administration of
the compound in vivo reduces cognitive decline and ameliorates neu-
ropathology in the cortex and hippocampus [79]. Endogenous Aβ 1–43
peptide expressed in these mice was found to block large conductance,
Ca2+-sensitive K+ (BK) channels and enhance CaV-mediated Ca2+ in-
flow in neocortical neurons [80].
Recently, promising results were reported on the neuroprotective
action of Anle138b in the APPPS1ΔE9 mouse model of AD [81].
Anle138b is a small molecule able to ameliorate amyloid plaque pa-
thology, LTP and spatial reference memory, with a mechanism invol-
ving inhibition of Ca2+ inflow through Aβ 1–42-formed pores. In ad-
dition to the restoration of physiological hippocampal operation and
cognitive skills, a complete rescue of wild type-like gene expression
profile was observed in treated animals. Importantly, the compound is
orally available, shows good blood brain barrier penetration and no
toxicity at therapeutic doses. Anle 138b is a promising neuroprotectant
also in other NDDs associated to toxic protein deposition. Indeed, the
compound showed capability to inhibit oligomer accumulation, neu-
ronal degeneration, and disease progression in vivo in three PD models
[82] and has recently been tested with success in an animal model of
Multiple System Atrophy [83].
ER Ca2+ pool undergoes severe dysregulation in AD mouse models,
including the 3XTgAD model. The aberrantly increased ER Ca2+ signals
are associated to AD-relevant mutations carried by the model and
mediated by RyR overexpression, suggestive of a specific pathogenic
pathway rather than a consequence of normal neuronal aging [84]. In a
follow-up study, it was reported the RyR blocker dantrolene is able to
normalize, in vitro, aberrant Ca2+ handling in AD mice [85]. A very
recent report has shown that HCN1 channels undergo perisomatic ER
sequestration in 3XTgAD mice. Therefore, HCN1 channels are mis-
localized in hippocampal CA1 pyramidal neurons, and normal soma-to-
dendrite expression gradient as well as dendritic integrative properties
are disrupted. Administration of dantrolene or cyclopiazonic acid (a
blocker of ER Ca2+ pump) restores expression levels of HCN1 channels
at cell surface and normalizes neuronal electrical properties in vitro. No
explanation is provided as to the possible link between the reported
alteration in HCN1 channels’ trafficking and neuronal degeneration
[86].
At present, the exploitation of IMs for the design of neuroprotective
medications has not reached the stage of clinical studies in AD. AD
pharmacotherapy is still based on the modest symptomatic efficacy
showed by potentiation of cholinergic transmission achieved with
cholinesterase inhibitors donepezil, rivastigmine and galantamine.
Memantine is also used in AD therapy [87]. As a low-affinity antagonist
of extrasynaptic NMDA receptors, the main mediators of the excitotoxic
component in neuronal degeneration, memantine was suggested to
have neuroprotective properties [88]. While several clinical studies
have provided evidence for some pro-cognitive symptomatic efficacy of
memantine, the presumed neuroprotective action of memantine has
never been clearly established and remains, at present, largely hy-
pothetical [87].
5. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is caused by the degeneration of
neurons controlling skeletal muscles, or motor neurons (MNs). Both
cortical and spinal MNs, often referred to as “upper” and “lower” MNs
respectively, are affected in the disease. Clinical manifestations include,
at onset, muscle stiffness, twitching, and weakness. Later on, as a result
of progressive neurodegeneration, muscles undergo atrophy, thus
leading to the inability to speak, swallow and, in final stages, breath
[89]. The causes of ALS are still largely unknown in sporadic forms,
which account for 90–95% of cases, while some important mechanistic
insight has emerged from the study of monogenic ALS forms. Several
mutations in the superoxide dismutase 1 (SOD1), a key enzyme in the
metabolism of reactive oxygen species, have been discovered in asso-
ciation with ALS [90]. Mice expressing the human SOD1 protein con-
taining the G93A mutation display degeneration of motor neurons
leading to paralysis and death at five months of age [91]. Notably,
deletion of endogenous SOD does not lead to the development of ALS
neuropathology and motor symptoms in mice [92], suggesting that
neuronal toxicity associated to SOD mutations is independent from
dismutase activity [93].
In the current view, ALS pathophysiology includes glutamate ex-
citoxicity, oxidative stress, mutant SOD1 enzymes, mitochondrial dys-
function and disruption of axonal transport processes [94]. Recent
studies have described dysfunction or aberrant subcellular localization
of wild type SOD1 in sporadic ALS, providing evidence that the im-
portance of this enzyme in ALS pathophysiology is not restricted to
genetic forms [90]. As downstream events triggered by ALS causes,
axonal hyperexcitability and associated glutamate receptor-mediated
excitotoxicity have emerged as major processes driving neurotoxicity.
Of note, cortical hyperexcitability, a neurological index of early ALS,
has been reported in carriers of SOD1 mutations before the onset of
clinical symptoms, suggesting a critical contribution of aberrant elec-
trical activity as a driver of ALS progression [89]. According to the
“dying forward” hypothesis, hyperactivity of cortical MNs induces
NMDA receptor-mediated excitotoxicity on spinal postsynaptic MNs
[95]. The SOD1 mouse model shows hyperexcitability and degeneration
of MNs, thus pointing to the presence of a mechanistic link between
ROS metabolism, alterations in IMs and neuronal degeneration. Ab-
normalities in Na+ and K+ conductances contribute to the development
of membrane hyperexcitability in ALS, thereby leading to disease
hallmarks such as muscle cramps and fasciculations, in addition to
promoting a neurodegenerative cascade via a number of Ca2+-
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mediated processes [96]. Among the Na+ conductances involved in
ALS-related axonal hyperexcitability, the persistent Na+ current (INap)
seems to play a pivotal role. INap is mediated by NaV 1.6 channels.
Compared to the other members of the NaV family, NaV 1.6 shows very
slow and incomplete inactivation. INap is functionally upregulated in
ALS animal models [97,98]. Furthermore, studies in both sporadic and
familial ALS patients reported alterations in axonal excitability con-
sistent with increased INap [99]. Upregulation of INap perturbs the
ionic homeostasis by increasing intracellular Na+ concentrations. In
turn, this results in reverse operation of the Na+/Ca2+ exchanger
(NCX). In physiological conditions, NCX exchanges intracellular Ca2+
with extracellular Na+ at 1:1 ratio. When the intracellular Na+ con-
centration is elevated, as in the presence of upregulated INap, NCX acts
as a symport, allowing inflow of both Na+ and Ca2+. This process,
besides directly elevating intracellular Ca2+, determines membrane
depolarization thus promoting further ER- and CaV-mediated Ca2+
entry with a feed-forward mechanism. The rise in intracellular Ca2+
levels is then thought to cause activate multiple cell death cascades
([100] [101,102],).
Compelling preclinical evidence that elevated neuronal excitability
and excitotoxicity are major determinants of ALS has prompted at-
tempts to develop neuroprotective treatments based on this rationale.
In fact, the only drug currently approved for ALS which shows some
disease-modifying efficacy is riluzole, which is supposed to exert its
neuroprotective activity by inhibiting NaV 1.6 channels and excessive
glutamate release. Collectively, data collected from randomized con-
trolled trials suggest that riluzole typically extends survival by 2–3
months, increasing by ˜9% the chance of an additional year of survival
[103], indicating a significant, yet modest, neuroprotective efficacy.
Based on a similar rationale, the NaV blocker and antiarrhythmic fle-
cainide was tested in a phase II clinical study. Due to the short duration
of the study (32 weeks) and relatively small sample (54 patients), the
study was not designed to detect evidence of disease-modifying prop-
erties, although flecainide groups showed significant improvement in
axonal conduction properties [104].
The evidence that pharmacological manipulation of a disease-spe-
cific IM has, although unsatisfactory, disease-modifying capacity in
clinical ALS, should encourage further exploration of this class of tar-
gets with basic and preclinical studies. Fig. 2 (middle) schematizes
major ALS-related alteration in IMs and in the electrical activity of the
affected neuron.
6. Spinocerebellar ataxia
Spinocerebellar ataxias (SCAs) are an aetiologically heterogeneous
group of movement disorders characterized by a relatively homo-
geneous set of clinical manifestations including alterations in gait, eye
and limb movement, and speech. A common pathological denominator
of SCAs is the involvement of Cerebellar Purkinje neurons (PNs), al-
though other cerebellar and brainstem neurons may be affected [105].
Although the severity of symptoms and degree of disability may vary to
a large extent, SCA is a progressive and irreversible disease often
leading to death, as no effective neuroprotective or symptomatic
treatments are available. In spite of the clinical similarities, the ae-
tiology of SCAs displays a great degree of diversity. In contrast with the
majority of NDDs, most SCAs have a known genetic cause. Over forty
mutations have been discovered to cause SCA with autosomal domi-
nant, autosomal recessive, or X-linked mechanism of inheritance [105].
This number keeps growing as new SCA causing mutations are de-
scribed [106]. As mentioned, PNs are typically most affected, and IMs
participate to neuropathology in a dual manner: 1) as primary disease-
causing factors when expressed in mutated forms; 2) as downstream
disease mechanisms activated by causing factors of other nature.
PNs are extremely large GABAergic neurons, with extensive den-
dritic arborisation, whose tonic, sustained AP firing (˜ 40 Hz) con-
stitutes the main output of the cerebellar cortex. Synaptic modulation of
tonic firing activity and GABA release on projection motor nuclei of the
brainstem is at the basis of the primary function of the cerebellum, i.e.,
the coordination of motor functions. The AP cycle in these neurons is
initiated by a subthreshold depolarization phase sustained by NaV 1.6.
When the potential approaches firing threshold, NaV 1.1 activate and
drive the AP upstroke. The next repolarization phase relies mainly on
the activation of KV 3.3 channels. CaV 2.1 and 3 are also activated
during the AP. The resulting Ca2+ entry, in turn, activates BK and SK
channels mediating the after-hyperpolarization (AHP). AHP permits
complete de-inactivation of NaV 1.6 which are now ready to start a new
AP cycle. Mutations in any of the ion channels governing this complex
process may disrupt AP cycle, normal Ca2+ homeostasis and, in some
cases, promote neuronal death. Mutations in the KCND3 gene, coding
for KV 4.3, cause SCA 19/22 [107]. These mutations result in reduced
surface expression and current density of the channel. Interestingly,
since the expression of KV 4.3 has not been clearly demonstrated in PNs,
the reason why these degenerate is still unclear. The presence of KV 4.3
in granule cells and molecular layer interneurons, two cerebellar neu-
ronal populations making direct synaptic contacts with PNs, suggests
the contribution of non-cell autonomous mechanisms, such as disrup-
tion of the excitation/inhibition balance and excitotoxicity [108].
Transient receptor potential channel type 3 (TRPC3) is a Ca2+-perme-
able, non-selective channel expressed in PNs, where it is essential for
the induction of Long-Term Depression in these neurons [109]. In hu-
mans, mutations in TRPC3 cause SCA41, in some cases associated to
neurodegeneration [110]. Consistently, a dominant gain-of-function
mutation (T635A) in TRPC3 causes motor impairment and progressive
PN degeneration in the moonwalker mice. In these mice, PN firing is
abnormally prone to depolarization block, suggesting that TRPC3 may
also be involved in the normal AP generation cycle [111].
In humans, mutations in the itpr1 gene, encoding the type 1 Inositol
1,4,5-trisphosphate receptor (IP3R1), are responsible for SCA15/16 and
SCA 29, two forms with very distinct clinical profile, with the former
characterized by adult-onset, slow-progressing ataxia and atrophy, the
latter by congenital-onset, non-progressive ataxia with additional cer-
ebellar dysfunctions [112]. The IP3R is a Ca2+ channel gated by IP3 and
expressed on the ER membrane. Engagement of IP3 signalling in PNs is
largely, although not solely, a consequence of type 1 metabotropic
glutamate receptor activation by excitatory afferents onto PNs [112].
Multiple studies have provided converging evidence that SCA15/16 is
caused by IP3R1 haploinsufficiency [113] and mice carrying sponta-
neous as well as engineered itpr1 mutations leading to reduced IP3R1
protein levels display neurological alterations consistent with the
human disease [114,115].
Poly glutamine (poly-Q) mutations account for the vast majority of
SCA cases. They consist in a variable expansion of the glutamine-en-
coding CAG repeat in the gene coding sequence. Among SCA-causing
mutations, SCA1, 2, 3, 6, 7 and 17 are caused by poly-Q-affected gene.
In SCA6, the poly-Q-expansion directly affects an IM encoding gene
(CACNA1A), which codes for the pore-forming subunit CaV 2.1.
Homozygous SCA6 [84Q] mice show alteration of PN electrical activity,
which is partially restored by administration of 4-aminopyridine, KV
blocker, KCa enhancer [116]. There is no evidence of neuropathology in
this strain [117], suggesting that SCA6 is a pure channelopathy. In the
remaining poly-Q SCAs, mutated genes are involved in transcriptional
regulation (ATXN1, ATXN7, TBP), RNA metabolism (ATXN2), protein
turnover and degradation (ATXN3). Mouse models of poly-Q SCAs have
revealed that downstream alterations in gene expression pattern and
molecular pathways are largely overlapping across mutations, and
many of the secondarily dysregulated pathways involve key IMs
[105,118]. SCA1 is caused by ATXN1 [82Q] mutation. ATXN1 is reg-
ulator of RNA transcription, and poly-Q expansion leads to transcrip-
tional and functional downregulation of BK and G-protein inward rec-
tifying K+ channels (GIRK; [119]). In transgenic mice carrying the
pathogenic mutation, PNs display depolarized membrane potential and
reduced AHP amplitude. In combination, these alterations lead to
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depolarization block due to the inability of NaV1.6 to fully de-inactivate
at the end of the descending phase of the AP. Dendritic atrophy has
been demonstrated during disease progression, a process that has been
interpreted as a homeostatic response able to partially restore BK and
GIRK current density, membrane potential value, AHP amplitude and
intrinsic AP firing [119]. In a mouse model of SCA2, associated to the
ATXN2 [127Q] mutation, transcriptional downregulation of BK and KV
3.3 channels is associated, early in disease progression, to disruption of
PN electrical activity. As in SCA1, near-normal PN spiking is restored by
compensatory IMs of uncertain nature. Nevertheless, later stages are
characterized by clear PN loss [120]. In ATXN2 [58Q], the mutated
protein interacts with the COOH terminal of the IP3R1, thus increasing
its sensitivity to IP3 and facilitating ER Ca2+ release. Interestingly, PN
degeneration and ataxia symptoms were alleviated by administration of
dantrolene in mice expressing the ATXN2 [58Q] mutation [121] The
ATXN3 [84Q] mutation is at the basis of SCA3, the most common SCA
with autosomal dominant inheritance. In this form, motor impairment
results, in the early phase, from alteration in PN firing. Later on, PN
degeneration occurs in a number of cases [122]. PN degeneration seems
to correlate with disrupted regulation of Ca2+ release from intracellular
stores, as ATXN3 interacts with the Ca2+ release machinery.
Collectively, results from studies on the numerous IMs-associated
forms of SCA indicate that defective ionic activity, via neuronal hy-
perexcitability and Ca2+ dishomeostasis, can promote both clinical
manifestations and neuropathology, including neuronal death.
Arguably, normalizing dysfunctional IMs would provide dual benefit.
SCA mutations are heterogenerous in nature and daunting in number,
making it extremely challenging targeting each of them for neuropro-
tection. However, studies on the most frequent forms (SCA1, 2, 3 and 6)
highlight the involvement of a relatively small number of dysfunctional
IMs across multiple aetiologies, such as KCa channels, and aberrant
Ca2+ release from intracellular stores. Fig. 2 (bottom) illustrates the
link between disruption of IMs and electrical activity with neuronal
death in SCA.
Based on the massive evidence of a causal role for the derangement
of intracellular Ca2+ handling in SCA, a number of attempt to target
these mechanisms have been made, albeit only at preclinical stage.
Pharmacological control of Ca2+ release from intracellular stores with
the RyR blocker dantrolene ameliorates motor performance and PN
degeneration in animal models of SCA 2 and 3 [121,123]. Similar re-
sults were obtained with viral-mediated overexpression of the IP3
phosphatase 5 P P in SCA2 mice [124].
In many SCA forms, neuronal degeneration arises as a consequence
of a deleterious electrical phenotype, rather than as a direct con-
sequence of the altered IM. As there is generally some degree of re-
dundancy in the IMs controlling the electrical properties of neurons,
any pharmacological intervention able to normalize such aberrant
phenotype, although not directly targeting the defective IM, may in
principle afford neuroprotective efficacy. Based on this line of rea-
soning, one laboratory has tested compounds able to normalize K+
currents in animal models of the disease. Chlorzoxazone, a KCa channels
activator, and baclofen, a GABAB receptor agonist, proved able to co-
operatively exert a partial rescue of the normal electrophysiological
phenotype of PNs in brain slices from ATXN1 [82Q] mice, and oral
coadministration ameliorated ataxia symptoms [125]. Interestingly, the
same work reports a retrospective study on patients with different SCA
forms, treated with chlorzoxazone and/or baclofen as a symptomatic
therapy. Results indicate that chlorzoxazone+ baclofen coadministra-
tion is well tolerated and that it provides some moderate improvement
in standard neurological tests.
Finally, the ALS drug riluzole is currently being tested in a phase
IIb/III, randomized, double-blind, placebo-controlled clinical study
(NCT02960893). The rationale of the latter study is the demonstrated
ability of riluzole to enhance activated KCa currents [105]. Although
preliminary, these results are promising and encourage additional ef-
forts aimed at testing the neuroprotective potential of additional IMs
modulators in preclinical models and extending the comprehension of
common ionic bases underlying distinct SCA forms.
7. Degenerative retinal disorders
Several diseases affecting the retina and leading to blindness are
associated to degeneration of retinal cells. These diseases will be col-
lectively referred to as degenerative retinal disorders (DRDs). In some
DRDs, the degenerating structure is the retinal pigment epithelium
(RPE), a basal layer of cells with trophic function. Some DRDs are
caused by mutations in organ-specific IMs. Mutations in the BEST1 gene
cause a subtype of DRDs, normally referred to as “bestrophinopathies”.
Over 200 BEST1 mutations have been discovered leading to the five
known bestrophinopathies. BEST1 codes for the Bestrophin 1 protein,
the single unit of a pentameric Ca2+-dependent anionic channel which
localizes to the basal membrane of RPE cells [126]. In addition to
functioning as an anion channel, Best1 also serves as a regulator of
intracellular Ca2+ signalling and homeostasis. [144,145].
Cyclic Nucleotide Gated (CNG) channels are key elements of the
phototransduction machinery in photoreceptors. The CNG family is
composed, in mammals, by six members, CNGA1-4, CNGB1 and
CNGB3. CNG channels are expressed in the outer segment of photo-
receptors and mediate the so called “dark current”, a mixed, non-in-
activating Na+/Ca2+ current, resulting in a depolarized (˜ −40mV)
potential and a tonic release of glutamate vesicles from the basal
membrane. Light stimulation leads to closure of CNG channels, mem-
brane hyperpolarization (˜ −65mV) and glutamate release cessation.
Several mutations in CNGA1 and CNGB1 genes have been associated to
RP. It is believed that 1–8% of retinitis pigmentosa (RP) cases are ac-
counted by mutations in these two genes [127]. CNGB1 KO mice show
early functional defect, followed by pathological sings of human RP,
including compromised rod-mediated vision and rod degeneration,
which later extend to cones [128]. Functional studies performed on RP-
causing CNGB1 mutations have uncovered a set of heterogeneous de-
fects ranging from functional inactivation to impaired channel targeting
or stability [129]. Therefore, it is unclear whether CNGB1-related RP
depends on disrupted ionic activity. Regardless of the nature of the
pathogenic pathways triggered by mutated CNG channels, there is
considerable ongoing effort in the development of Adeno-Associated
Virus (AAV)-mediated gene therapies for RP cure. Following the path
opened by Luxturna©, a recently approved cure for RPE65-associated
retinal dystrophy [130], preclinical studies are testing the efficacy of
AAV-based gene supplementation therapy for CNGB1-linked RP45
[131].
8. Conclusion and perspectives
Neuroprotection is the main unmet medical need in the manage-
ment of NDDs. Incomplete understanding of the underlying pathogenic
mechanisms explains, at least in part, the substantial failure in the
development of disease-modifying approaches [23]. Indeed, preclinical
and genetic studies have uncovered an unexpected level of complexity
and diversity in the molecular pathways implicated within individual
NDDs [132]. It is now increasingly recognized that classical NDD de-
finitions, mainly based on neurological assessment, neuroimaging and
post-mortem neuropathological evaluation, are inadequate to reveal the
multifaceted nature of each pathology. In the future, effective genetic
profiling will likely reshape classical definitions and, hopefully, guide
targeted therapy. On the diagnostic side, provided that reliable bio-
markers and instrumental methods for earlier diagnosis are available,
affected individuals will be genetically profiled and diagnosed with a
specific NDD molecular subtype, ideally before symptoms onset, in time
for state-of-the-art therapy. On the therapeutic side, however, un-
ravelling all the mechanistic complexity of a given NDD implies that
physicians will have to face multiple diseases instead of one. The task
appears overly challenging also for pharmacologists in their effort to
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develop tools with disease-modifying capability, as the number of
pathways with pathogenic relevance in NDDs is constantly rising. On
the one hand, extending our molecular understanding of NDDs, espe-
cially in sporadic forms, is of paramount importance to unravel new
specific targets. On the other hand, exploiting targets with relevance
across pathways may simplify and expedite the development of effec-
tive compounds. In this regard, compelling evidence suggests that the
number of NDD-associated dysfunctional IMs is quite limited as com-
pared to the complexity of upstream pathways. In addition, certain
electrophysiological alterations have been associated to neurodegen-
eration in distinct NDDs, suggesting that pharmacological correction of
a given pathological electrical phenotype may have neuroprotective
efficacy in multiple pathologies [133–136].
Evidence for a strong causal link between IMs and neuronal death is
compelling for many NDDs (Table 1). Dissection of the electro-
physiological alterations characterizing NDDs at cellular level, largely
provided by excellent functional studies in animal models, clearly
points to the existence of electrical phenotypes promoting cellular pa-
thology. Depending on the NDD class and the disease pathway re-
capitulated in the animal model, electrical phenotype promoting vul-
nerability may be innate or acquired. In PD models, both normal
electrical properties (CaV1.3-mediated dendritic Ca2+ activity) or ac-
quired alterations (i.e. aberrant firing rate, increased synaptic excit-
ability) resulting from the activation of specific disease pathways (α-
synuclein signalling, UPS inhibition, metabolic stress) have been im-
plied in the selective vulnerability of midbrain dopaminergic neurons
[38,39,53,137]. In particular, Ca2+ activity is emerging as a pathogenic
component with broad relevance in PD forms with multiple aetiologies
[41,43,46]. In terms of therapeutic perspectives, the pharmacological
correction of the “risky” electrical phenotype appears amenable, as
shown by the case of isradipine, a dihydropyridine targeting CaV 1.2
and 1.3, previously approved for the treatment of high blood pressure
and now undergoing a re-purposing process whose rationale is provided
by the comprehension of the electrical determinants of dopaminergic
vulnerability in PD [138,139]. If successful, the isradipine study will
not only provide the first available disease-modifying pharmacological
tool in PD, but also pave the way for the exploration of other IMs as
neuroprotective targets.
Dysregulated Ca2+ handling has also been extensively linked to the
pathogenesis of AD [69,140]. However, observational studies on co-
horts of subjects taking Ca2+ antagonists for cardiovascular diseases
have provided controversial results [141]. An alternate strategy is tar-
geting ER Ca2+ channels, such as the RyR and IP3R [142]. Indeed,
modulating ER Ca2+ with the RyR blocker and ER stabilizer dantrolene
has proven effective in animal models [70]. The translation of dan-
trolene to the clinical setting is however limited by the poor brain pe-
netrance, which warrants future chemical reformulation of the com-
pound.
Certain risky electrophysiological profiles are shared by distinct
NDDs. As a consequence, drugs correcting such profiles may provide
cross-disease neuroprotective efficacy. The concept of the cross-disease
relevance of IMs is well exemplified by ALS and SCA. In both disorders,
aberrant neuronal excitability and excitotoxicity have been proposed as
powerful drivers of neurodegeneration [89,105]. The existence of a
similar hyperexcitable profile in ALS and SCA [96,108] provides a
strong rationale for the protective action of riluzole, a NaV blocker re-
ducing excessive spiking. Although the protective efficacy of riluzole is
limited in ALS and still under clinical evaluation in SCA, the example
highlights the potential of an approach targeting electrical alterations,
especially when these have similar relevance in multiple disorders.
In all areas of pharmacology, a major obstacle that must be over-
come when exploring new targets is the possible lack of target speci-
ficity. IMs involved in neurodegenerative processes are not, with few
exceptions, expressed exclusively in the neuronal populations at risk or
as a result of NDD-specific pathogenic cascades. In fact, most of the IMs
discussed in the present review are broadly expressed within and even
outside the CNS. Raising the lipophilicity of promising molecules may
help the achievement of effective concentrations in the nervous tissue
avoiding dose-limiting peripheral side effects. An even greater chal-
lenge is posed by the need to limit off-target effects within the CNS. The
issue of selectivity may be overcome by engineering drugs with better
target specificity on one side, or by identifying new targets with
stronger disease specificity on the other side. In this respect, some de-
gree of selectivity may be afforded by the fact that target mechanisms
are often aberrantly functional in the involved population and thus
possibly more sensitive to the effects of a modulation in the opposite
direction.
In conclusion, it is our opinion that pharmacological research
should intensify its effort on the exploration of IMs as targets for neu-
roprotectants in diseases where preclinical studies point to the existence
of a pathogenic electrical component. The paradigmatic case of isra-
dipine highlights another important potential advantage of harnessing
IMs, i.e. the opportunity to feed fast-track repositioning programs by
gleaning from the enormous armamentarium of available, safe com-
pounds acting on this target category.
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